title: The long-term efficacy, 13-23 years, of a plasma-derived hepatitis B vaccine in highly endemic areas in China.
abstract: OBJECTIVE
  To evaluate the long-term effectiveness of the plasma-derived hepatitis B vaccine that has been applied widely in five areas of China where HBV prevalence was highly endemic.
  
  
  METHODS
  A cross-sectional investigation was conducted in 2009 at five HBV surveillance sites around China. The target study subjects of 6772 were born between 1986 and 1996 and received plasma-derived HBV vaccine. Serum samples were collected to test for HBV markers using the microparticle enzyme immunoassay.
  
  
  RESULTS
  The number of participants enrolled was 6772. The average hepatitis B surface antigen (HBsAg) prevalence was 2.01%. The birth dose group included 5052 children. In this group, the average positive rates of HBsAg and hepatitis B core antibody (anti-HBc) were 1.58% and 6.39%, respectively, and these values declined gradually from 1986 to 1996. The positive rates of anti-hepatitis B surface antibody (HBs) and the geometric mean concentration (GMC) of anti-HBs-positive subjects were 41.69% and 115.8mIU/ml.
  
  
  CONCLUSIONS
  The long-term effectiveness of the plasma-derived hepatitis B vaccine still provided protection 13-23 years after vaccination. It seems that a booster dose is not necessary. Enhancing the rate of the birth dose within 24h is one of the most important measures to prevent and control HBV infection.
authors.affiliation: Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping District, Beijing 102206, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Wang
authors.affiliation: Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping District, Beijing 102206, China.
authors.forename: Liping
authors.initials: L
authors.lastname: Shen
authors.affiliation: National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100052, China.
authors.forename: Fuqiang
authors.initials: F
authors.lastname: Cui
authors.affiliation: Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping District, Beijing 102206, China.
authors.forename: Shuang
authors.initials: S
authors.lastname: Zhang
authors.affiliation: National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100052, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Zheng
authors.affiliation: Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping District, Beijing 102206, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100052, China.
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Liang
authors.affiliation: National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100052, China. Electronic address: wfznip2@163.com.
authors.forename: Fuzhen
authors.initials: F
authors.lastname: Wang
authors.affiliation: Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping District, Beijing 102206, China. Electronic address: shengli_bi@163.com.
authors.forename: Shengli
authors.initials: S
authors.lastname: Bi
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D003430:Cross-Sectional Studies; D019353:Endemic Diseases; D005260:Female; D006509:Hepatitis B / Q000453:epidemiology* / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D055815:Young Adult
chemical_list: D017325:Hepatitis B Vaccines
keywords: Hepatitis B vaccination; Hepatitis B virus; Long-term efficacy